Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis - PubMed (original) (raw)

Observational Study

. 2014 Jul 15;190(2):175-84.

doi: 10.1164/rccm.201404-0703OC.

Sonya L Heltshe, Tanja Gonska, Scott H Donaldson, Drucy Borowitz, Daniel Gelfond, Scott D Sagel, Umer Khan, Nicole Mayer-Hamblett, Jill M Van Dalfsen, Elizabeth Joseloff, Bonnie W Ramsey; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network

Collaborators, Affiliations

Observational Study

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

Steven M Rowe et al. Am J Respir Crit Care Med. 2014.

Abstract

Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation.

Objectives: To evaluate ivacaftor in a postapproval setting and determine mechanism of action and response of clinically relevant markers.

Methods: We conducted a longitudinal cohort study in 2012-2013 in G551D CF patients age 6 and older with no prior exposure to ivacaftor. Study assessments were performed at baseline, 1, 3, and 6 months after ivacaftor initiation. Substudies evaluated mucociliary clearance, β-adrenergic sweat secretion rate, gastrointestinal pH, and sputum inflammation and microbiology Measurements and Main Results: A total of 151 of 153 subjects were prescribed ivacaftor and 88% completed the study through 6 months. FEV1 % predicted improved from baseline to 6 months (mean absolute change, 6.7%; P < 0.001). Similarly, body mass index improved from baseline to 6 months (mean change, 0.8 kg/m(2); P < 0.001). Sweat chloride decreased from baseline to 6 months (mean change, -53.8 mmol/L; 95% confidence interval, -57.7 to -49.9; P < 0.001), reflecting augmented CFTR function. There was significant improvement in hospitalization rate (P < 0.001) and Pseudomonas aeruginosa burden (P < 0.01). Significant improvements in mucociliary clearance (P < 0.001), gastrointestinal pH (P = 0.001), and microbiome were also observed, providing clinical mechanisms underlying the therapeutic benefit of ivacaftor.

Conclusions: Significant clinical and physiologic improvements were observed on initiation of ivacaftor in a broad patient population, including reduced infection with P. aeruginosa. Biomarker studies substantially improve the understanding of the mechanistic consequences of CFTR modulation on pulmonary and gastrointestinal physiology.

Keywords: CFTR modulator; Pseudomonas aeruginosa; cystic fibrosis; ivacaftor; pH.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Diagram of participants screened, eligible, enrolled in core and substudies, follow-up, and withdrawals.

Figure 2.

Figure 2.

Clinical measures at baseline, 1, 3, and 6 months postivacaftor. (A) FEV1 percent predicted. Change from baseline in (B) body mass index (BMI) and (C) sweat chloride. (D) Change from baseline in Cystic Fibrosis Questionnaire-Revised (CFQR) Respiratory Score. Means and 95% confidence intervals. Horizontal hashed line in D at_4_ represents minimal clinically important difference (41).

Figure 3.

Figure 3.

Clinical measures obtained through Cystic Fibrosis Foundation National Patient Registry in 6-month intervals preivacaftor and postivacaftor. (A) Participants with at least one hospitalization and (B)Pseudomonas aeruginosa positivity among those with a recorded respiratory culture in 6-month intervals. Means and 95% confidence intervals; *P < 0.001.

Figure 4.

Figure 4.

Substudy mucociliary clearance (A) mean particle retention curves from the whole right lung at baseline and 1 month following ivacaftor treatment. (B) Average (± SD) whole lung clearance for 60 minutes after inhaling Tc99m-SC aerosol. *P < 0.001 versus baseline.

Figure 5.

Figure 5.

Substudy small intestinal pH profile. Mean pH readings every minute at baseline (gray) and 1 month postivacaftor (black). GE = gastric emptying.

Comment in

References

    1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001. -PubMed
    1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689. -PubMed
    1. Gelfond D, Borowitz D.Gastrointestinal complications of cystic fibrosis Clin Gastroenterol Hepatol 201311333–342.quiz e330–331 -PubMed
    1. Collie JT, Massie RJ, Jones OA, Legrys VA, Greaves RF. Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis. Pediatr Pulmonol. 2014;49:106–117. -PubMed
    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation National Patient Registry annual data report 2012. Bethesda, MD: Cystic Fibrosis Foundation; 2013

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources